Fulgent Genetics Inc., El Monte, California, a technology-based company with a laboratory services business and a therapeutic development business, announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics, Alpharetta, Georgia, and to acquire StrataDx, Lexington, Massachusetts. The proposed acquisition will add new anatomic pathology services, proprietary PCR tests, and a national client base. Fulgent will acquire certain assets of Bako Diagnostics and will acquire StrataDx for a total combined purchase price of about $55.5 million, subject to adjustments, to be paid from cash on hand. The acquisition is expected to close during the first half of 2026, subject to satisfying customary closing conditions, including regulatory approvals. With these additions, Fulgent will further strengthen its laboratory services business by adding new products and services and further expand its national client base, national sales team, and team of expert pathologists.
Bako Diagnostics is a national provider of specialty laboratory testing services, which offers a comprehensive testing menu, including complete anatomic pathology services, proprietary molecular genetic testing, and peripheral neuropathy immuno-histochemical testing. Bako Diagnostics is CLIA certified, CAP accredited, and licensed by the Georgia Department of Public Health.
StrataDx is a premier national provider of dermatopathology testing services. StrataDx is CLIA certified, CAP accredited, and licensed by the State of Massachusetts.
